MedTrace Logo

Risk Assessment for HBV-Related Liver Cancer

NCT07160946 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2025-09-08

No results posted yet for this study

Summary

Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.

Conditions

  • HBV-related Liver Cirrhosis

Interventions

OTHER

AI folow-up system

In AI follow-up group, patients will be followed up by an AI system.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-10
Primary Completion
2032-12-30
Completion
2032-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07160946 on ClinicalTrials.gov